Abeona Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>AT</div>
ABEO -- USA Stock  

USD 1.79  0.13  6.77%

Abeona Therapeutics PPandE Turnover is quite stable at the moment as compared to the past year. The company's current value of PPandE Turnover is estimated at 0.66. Receivables Turnover is expected to rise to 30.97 this year, although the value of Net Income Per Employee will most likely fall to (935.3 K). In this article, we will outline Abeona Therapeutics. We will evaluate why we are still optimistic in anticipation of a recovery. In this post, I will also go over some essential variables affecting Abeona Therapeutics' products, and show how it may impact Abeona Therapeutics outlook for active traders this year.
Published over a month ago
View all stories for Abeona Therapeutics | View All Stories
Is Abeona Therapeutics overvalued?
The firm shows a Beta (market volatility) of 0.5863, which signifies possible diversification benefits within a given portfolio. Let's try to break down what Abeona's beta means in this case. As returns on the market increase, Abeona Therapeutics returns are expected to increase less than the market. However, during the bear market, the loss on holding Abeona Therapeutics will be expected to be smaller as well. Even though it is essential to pay attention to Abeona Therapeutics historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy in foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Abeona Therapeutics exposes twenty-one different technical indicators, which can help you to evaluate its performance. Abeona Therapeutics has an expected return of -0.0923%. Please be advised to confirm Abeona Therapeutics jensen alpha, and the relationship between the coefficient of variation and potential upside to decide if Abeona Therapeutics stock performance from the past will be repeated at some point in the near future.

How important is Abeona Therapeutics's Liquidity

Abeona Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Abeona Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Abeona Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Abeona Therapeutics's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Abeona Therapeutics, but it might be worth checking our own buy vs. sell analysis

Sale by Sco Capital Partners Llc of 1989 shares of Abeona Therapeutics

Legal trades by Abeona Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Abeona insider trading alert for sale of common stock by Sco Capital Partners Llc, the corporate stakeholder, on 17th of September 2020. This event was filed by Abeona Therapeutics Inc with SEC on 2020-09-17. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Abeona Therapeutics has an asset utilization ratio of 2.97 percent. This suggests that the company is making $0.0297 for each dollar of assets. An increasing asset utilization means that Abeona Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.

Another 3 percent slide for Abeona Therapeutics

Abeona Therapeutics latest skewness surges over 1.23. As of the 9th of August, Abeona Therapeutics shows the mean deviation of 4.11, and Risk Adjusted Performance of 0.1205. Abeona Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Abeona Therapeutics, which can be compared to its rivals. Please confirm Abeona Therapeutics jensen alpha, and the relationship between the coefficient of variation and potential upside to decide if Abeona Therapeutics is priced correctly, providing market reflects its regular price of 2.86 per share. Please also double-check Abeona Therapeutics total risk alpha, which is currently at (0.40) to validate the company can sustain itself at a future point.

Our Final Perspective on Abeona Therapeutics

Whereas some other firms in the biotechnology industry are either recovering or due for a correction, Abeona Therapeutics may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current Abeona valuation and our trade advice on Abeona Therapeutics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Abeona Therapeutics.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Abeona Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com